CellsBin Raises Series A Led by 108 BioCapital for Rare-Cell Intelligence Platform

CellsBin Raises Series A

CellsBin, a Branford, Connecticut-based tech-bio company, has raised a Series A round led by 108 BioCapital. The funding was announced on September 22, 2026. 108 BioCapital is the sole listed investor in the round.

What CellsBin Does

CellsBin is pioneering what it calls Rare-Cell Biology — the study of the rare cells that shape human health. The company's Rare-Cell Intelligence platform combines several advanced technologies:

• Advanced microfluidics
• Patented multimodal imaging
• Single-cell analysis
• Artificial intelligence

Together, these capabilities are designed to detect, characterize, and monitor rare cells at scale. The goal is to make biological signals that conventional methods miss visible, measurable, and actionable.

Initial Applications

CellsBin's initial applications focus on two areas:

• Cell and gene therapy monitoring
• Hematologic cancers

Both areas depend on detecting and tracking rare cells — populations that are typically difficult to isolate and analyze with standard techniques. CellsBin's platform is built specifically for that challenge.

Operations and Partnerships

CellsBin operates its headquarters and a CLIA laboratory in Branford, Connecticut. The company also partners with academic and medical centers, including Yale University.

The combination of an in-house CLIA lab and academic partnerships suggests a company structured to move between research-grade discovery and clinically relevant testing. The CLIA laboratory designation is significant for a company whose applications touch therapy monitoring and cancer.

Why Rare-Cell Biology Matters

Rare cells are often the most informative cells in a biological sample. In cell and gene therapy, tracking rare cell populations can inform whether a therapy is working. In hematologic cancers, rare cells can carry signals about disease presence and progression.

The problem is that conventional methods often miss these signals entirely. CellsBin's thesis is that microfluidics, multimodal imaging, single-cell analysis, and AI can be combined to surface them reliably and at scale — turning what was previously invisible into something measurable and actionable.

What the Round Signals

A Series A led by 108 BioCapital marks a transition point for CellsBin. Key signals for market observers:

• Lead investor conviction. 108 BioCapital led the round, indicating focused institutional backing for the company's Rare-Cell Intelligence platform.
• Stage. Series A funding typically supports scaling a platform beyond initial validation — in this case, expanding the reach of a technology that spans microfluidics, imaging, single-cell analysis, and AI.
• Application focus. Cell and gene therapy monitoring and hematologic cancers are concrete initial markets, giving the platform clear near-term use cases.
• Infrastructure in place. The company already operates a CLIA laboratory alongside its headquarters, suggesting it has built the operational foundation to support clinical-adjacent work.
• Academic ties. Partnerships with academic and medical centers, including Yale University, provide a research and validation network.

The Platform in Brief

CellsBin's Rare-Cell Intelligence platform is built around a multi-technology stack:

• Microfluidics for handling and isolating rare cells
• Patented multimodal imaging for characterization
• Single-cell analysis for granular biological insight
• AI for detection, characterization, and monitoring at scale

The company's stated aim is to make rare-cell signals visible, measurable, and actionable — a phrase that captures both the technical challenge and the clinical promise.

Looking Ahead

With a Series A led by 108 BioCapital, CellsBin is positioned to advance its Rare-Cell Intelligence platform and its initial applications in cell and gene therapy monitoring and hematologic cancers. The round, announced September 22, 2026, provides the company with backing as it continues to operate from Branford, Connecticut, and to build on its partnerships with academic and medical centers.

For those tracking tech-bio platforms at the intersection of microfluidics, imaging, and AI, CellsBin is a company to watch.